摘要
目的探讨人上皮卵巢癌组织中诱骗受体3(DcR3)的表达与预后的关系。方法选取88例人上皮卵巢癌组织标本、88例良性卵巢肿瘤组织标本,采用免疫组化染色分析2组标本中的DcR3蛋白表达差异,并依据国际妇产联盟分期(FIGO)、淋巴结转移情况、组织学分级、病灶大小、病理学类型进行分层,采用Cox比例风险回归模型分析DcR3的表达与患者预后的关系。结果卵巢癌组织中的DcR3蛋白阳性表达率(61.36%)高于良性组(28.41%),差异具有统计学意义(P<0.05)。经分析,不同FIGO分期、是否发生淋巴结转移、不同组织学分级的卵巢癌组织中的DcR3蛋白阳性表达率比较,差异具有统计学意义(P<0.05);Cox比例风险回归模型分析,DcR3蛋白阳性表达、FIGO分期增高、发生淋巴结转移、组织学高分级是卵巢癌患者不良预后的独立性危险因素(P<0.05)。结论人上皮卵巢癌组织中DcR3蛋白表达上调,并且与肿瘤的恶性程度增加、不良预后相关。
Objective To investigate the relationship between the expression of decoy receptor 3(DcR3)in human epithelial ovarian cancer tissues and the prognosis of patients.Methods 88 human epithelial ovarian cancer tissue specimens and 88 benign ovarian tumor tissue specimens were selected.Immunohistochemical staining was used to analyze the difference of DcR3 protein expression in the 2 groups,and according to the international maternity alliance stage(FIGO)),lymph node metastasis,histological grade,lesion size,pathological type were stratified,and Cox proportional hazards regression model was used to analyze the relationship between DcR3 expression and patient prognosis.Results The positive expression rate of DcR3 protein in ovarian cancer tissues was 61.36%higher than that in benign group(28.41%),the difference was statistically significant(P<0.05).After analysis,the positive expression rate of DcR3 protein in ovarian cancer tissues was different in FIGO stage.Compared with ovarian cancer with different histological grades,the difference was statistically significant(P<0.05).The Cox proportional hazard regression model analysis showed that DcR3 protein positive expression,FIGO staging increased,lymph node metastasis,and histological high grade were Independent risk factors for poor prognosis in patients with ovarian cancer(P<0.05).Conclusion The expression of DcR3 protein is up-regulated in human epithelial ovarian cancer tissues and is associated with increased malignancy and poor prognosis in patients with tumors.
作者
邢燕平
任红娟
王欣
XING Yanping;REN Hongjuan;WANG Xin(Nanyang Central Hospital,Nanyang,473009)
出处
《实用癌症杂志》
2022年第5期736-738,742,共4页
The Practical Journal of Cancer
基金
河南省医学科技攻关计划项目(编号:2019120887)。
关键词
人上皮卵巢癌
诱骗受体3
预后
病理学
Human epithelial ovarian cancer
Decoy receptor 3
Prognosis
Pathology
